-
1.发明公开
公开(公告)号：EP2714031A1
公开(公告)日：2014-04-09
申请号：EP12738184.6
申请日：2012-05-30
IPC分类号： A61K31/337 , A61K31/4025 , A61K31/4412 , A61K31/513 , A61K31/517 , A61K33/24 , A61P35/00 , A61K39/395
CPC分类号： A61K31/4025 , A61K31/282 , A61K31/337 , A61K31/44 , A61K31/513 , A61K31/517 , A61K33/24 , A61K39/39558 , A61K2300/00
摘要： or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents selected from sorafenib, lapatinib, erlotinib, cisplatin, 5-fluorouracil, docetaxel or cetuximab or a pharmaceutically acceptable salt thereof. The said pharmaceutical combination exhibits synergy when used in the treatment of squamous cell carcinoma of head and neck (SCCHN). The invention also relates to a pharmaceutical composition comprising the said combination and a method for the treatment of squamous cell carcinoma of head and neck (SCCHN), using a therapeutically effective amount of said combination.
摘要翻译： 本发明涉及一种用于在鳞状细胞癌的治疗中使用的药物组合，其包含由式（I）的化合物中选择的CDK抑制剂; 或其药学上可接受的盐和选自索拉非尼，拉帕替尼，厄洛替尼，顺铂，5-氟尿嘧啶，多西他赛或西妥昔单抗或其可药用的盐中选择的一种或多种抗肿瘤剂。 所述药物组合显示协同作用当在头部和颈部（SCCHN）的鳞状细胞癌的治疗中使用。 因此，本发明涉及包含所述组合以及用于治疗头部和颈部（SCCHN）的鳞状细胞癌，使用治疗有效量的所述组合的方法的药物组合物。
-
2.发明公开A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA 审中-公开药剂师ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON MELANOMEN
公开(公告)号：EP3019166A1
公开(公告)日：2016-05-18
申请号：EP14822283.9
申请日：2014-07-11
发明人： AGARWAL, Veena , PERIYASAMY, Giridharan , RATHOS, Maggie , SRIVASTAVA, Ankita , SRINIVASA, Sreesha
IPC分类号： A61K31/4025 , A61P35/00
CPC分类号： A61K31/4025 , A61K31/437 , A61K31/506 , A61K31/519 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor, for use in the treatment of melanoma. The present invention also relates to a method for the treatment of melanoma comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor.
摘要翻译： 本发明涉及包含由式I化合物（如本文所述）表示的细胞周期蛋白依赖性激酶（CDK）抑制剂或其药学上可接受的盐的药物组合; 和选自BRAF抑制剂或MEK抑制剂的至少一种抗癌剂，用于治疗黑素瘤。 本发明还涉及一种治疗黑素瘤的方法，包括向有需要的受试者施用治疗有效量的CDK抑制剂和治疗有效量的至少一种选自BRAF抑制剂或MEK抑制剂的抗癌剂 。
-
公开(公告)号：EP2714031B1
公开(公告)日：2018-05-23
申请号：EP12738184.6
申请日：2012-05-30
IPC分类号： A61K31/337 , A61K31/4025 , A61K31/4412 , A61K31/513 , A61K31/517 , A61K33/24 , A61P35/00 , A61K39/395
CPC分类号： A61K31/4025 , A61K31/282 , A61K31/337 , A61K31/44 , A61K31/513 , A61K31/517 , A61K33/24 , A61K39/39558 , A61K2300/00
摘要： or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents selected from sorafenib, lapatinib, erlotinib, cisplatin, 5-fluorouracil, docetaxel or cetuximab or a pharmaceutically acceptable salt thereof. The said pharmaceutical combination exhibits synergy when used in the treatment of squamous cell carcinoma of head and neck (SCCHN). The invention also relates to a pharmaceutical composition comprising the said combination and a method for the treatment of squamous cell carcinoma of head and neck (SCCHN), using a therapeutically effective amount of said combination.
-
公开(公告)号：EP3019166B1
公开(公告)日：2019-05-08
申请号：EP14822283.9
申请日：2014-07-11
发明人： AGARWAL, Veena , PERIYASAMY, Giridharan , RATHOS, Maggie , SRIVASTAVA, Ankita , SRINIVASA, Sreesha
IPC分类号： A61K31/4025 , A61P35/00
-
-
-
搜索结果
4 条记录 (耗时 0.009 秒)
